Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Merck & Company (MRK)

Merck & Company (MRK)
79.44 x 1 80.10 x 1
Pre-market by (Cboe BZX)
79.84 +1.10 (+1.40%) 04/24/25 [NYSE]
79.44 x 1 80.10 x 1
Pre-market 79.80 -0.04 (-0.05%) 05:44 ET
Profile for Thu, Apr 24th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.

Company Info

Merck & Company 126 East Lincoln Avenue Rahway NJ 07065 USA

www.merck.com Employees: 75,000 P: 908-740-4000

Sector:

Medical

Description:

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.

Key Statistics

Overview:

Market Capitalization, $K 201,337,248
Enterprise Value, $K 222,557,248
Shares Outstanding, K 2,521,759
Annual Sales, $ 64,168 M
Annual Net Income, $ 17,117 M
Last Quarter Sales, $ 15,624 M
Last Quarter Net Income, $ 3,743 M
EBIT, $ 20,221 M
EBITDA, $ 24,720 M
60-Month Beta 0.40
% of Insider Shareholders 0.09%
% of Institutional Shareholders 76.07%
Float, K 2,519,490
% Float 99.91%
Short Volume Ratio 0.40

Growth:

1-Year Return -37.13%
3-Year Return -9.98%
5-Year Return 2.79%
5-Year Revenue Growth 36.99%
5-Year Earnings Growth 47.40%
5-Year Dividend Growth 38.05%

Per-Share Information:

Most Recent Earnings 2.22 on 04/24/25
Next Earnings Date N/A
Earnings Per Share ttm 7.64
EPS Growth vs. Prev Qtr 9.55%
EPS Growth vs. Prev Year 5,633.33%
Annual Dividend Rate, $ 3.16
Annual Dividend Yield 3.96%
Most Recent Dividend 0.810 on 03/17/25
Next Ex-Dividends Date 03/17/25
Dividend Payable Date 04/07/25
Dividend Payout Ratio 40.63%
Most Recent Split 2-1 on 02/17/99

MRK Ratios

Ratio
Price/Earnings ttm 10.31
Price/Earnings forward 8.86
Price/Earnings to Growth 0.72
Return-on-Equity % 44.44%
Return-on-Assets % 17.17%
Profit Margin % 26.68%
Debt/Equity 0.74
Price/Sales 3.09
Price/Cash Flow 8.34
Price/Book 4.31
Book Value/Share 18.33
Interest Coverage 2.84

MRK Dividends

Date Value
03/17/25 $0.8100
12/16/24 $0.8100
09/16/24 $0.7700
06/17/24 $0.7700
03/14/24 $0.7700
12/14/23 $0.7700
09/14/23 $0.7300
06/14/23 $0.7300
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective